戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d with histologically confirmed, symptomatic Castleman disease.
2 red by patients with idiopathic multicentric Castleman disease.
3 between PEL and KSHV-associated multicentric Castleman disease.
4  (IL)-6 related KSHV-associated multicentric Castleman disease.
5 osi sarcoma, body cavity-based lymphoma, and Castleman disease.
6  primary effusion lymphoma, and multicentric Castleman disease.
7 ary effusion lymphoma (PEL) and multicentric Castleman disease.
8  TbetaRII in Kaposi sarcoma and multicentric Castleman disease.
9 primary effusion lymphoma, and some cases of Castleman disease.
10 posi sarcoma, primary effusion lymphoma, and Castleman disease.
11 ry effusion lymphoma (PEL), and multicentric Castleman disease.
12 ry effusion lymphoma (PEL), and multicentric Castleman disease.
13 entation as having localized or multicentric Castleman disease.
14 s primary effusion lymphoma and multicentric Castleman disease.
15 I 0.26-1.52): 3 skin-only KS, 1 multicentric Castleman disease, 1 allograft KS.
16                                              Castleman disease, an unusual condition of unknown cause
17 herapies successful in the treatment of both Castleman disease and associated autoimmune disease.
18 hieving long-term remission in patients with Castleman disease and associated autoimmune features.
19   This review focuses on the intersection of Castleman disease and autoimmunity with an emphasis on s
20 teritis, as well as other conditions such as Castleman disease and cytokine release syndrome.
21                                 Multicentric Castleman disease and hemophagocytic syndrome are other
22 ase (2 with visceral KS, 1 with multicentric Castleman disease, and 1 with primary effusion lymphoma)
23                   Localized and multicentric Castleman disease are different clinical disorders with
24  diagnosed with KSHV-associated multicentric Castleman disease at autopsy.
25 er primary effusion lymphoma or multicentric Castleman disease B-cell malignancies, and from polyclon
26                                              Castleman disease can occur in association with autoimmu
27                                              Castleman disease (CD) describes a group of at least 4 d
28                                              Castleman disease (CD) in the context of human immunodef
29                                              Castleman disease (CD) is a lymphoproliferative disorder
30                                              Castleman disease (CD) is a rare hematologic disorder ch
31                                              Castleman disease (CD), a heterogeneous group of disorde
32 etermine the cellular and molecular basis of Castleman Disease (CD), we analyze the spatial proteome
33  recent progress has been coordinated by the Castleman Disease Collaborative Network (CDCN), and furt
34      Castleman's Awareness & Research Effort/Castleman Disease Collaborative Network, Penn Center for
35 ry effusion lymphoma (PEL), and multicentric Castleman disease, encodes four interferon regulatory fa
36 ganomegaly, potentially including coexisting Castleman disease, endocrinopathy, monoclonal plasma cel
37 d herpesvirus (KSHV)-associated multicentric Castleman disease has increased.
38 ng of pathogenic cell types and cytokines in Castleman disease have allowed the development of target
39 inical types (localized and multicentric) of Castleman disease have been described.
40      Rational approaches to the treatment of Castleman disease have begun to have an impact on diseas
41 ces in understanding the biological basis of Castleman disease have provided new targets for therapeu
42                  HIV-associated multicentric Castleman disease (HIV MCD) is a rare lymphoproliferativ
43 ful treatment of HIV-associated multicentric Castleman disease (HIV+MCD) with rituximab-based approac
44                  HIV-associated multicentric Castleman disease (HIV-MCD) is a rare lymphoproliferativ
45                  HIV-associated multicentric Castleman disease (HIV-MCD) presents with systemic sympt
46                      Idiopathic multicentric Castleman disease (iMCD) is a hematologic illness involv
47                      Idiopathic multicentric Castleman disease (iMCD) is a rare and poorly understood
48                      Idiopathic multicentric Castleman disease (iMCD) is a rare and poorly-understood
49                      Idiopathic multicentric Castleman disease (iMCD) is a rare cytokine-driven disor
50                      Idiopathic multicentric Castleman disease (iMCD) is a rare hematologic illness o
51  clinical subtype of idiopathic multicentric Castleman disease (iMCD), consists of a constellation of
52 s primary effusion lymphoma and multicentric Castleman disease in AIDS patients.
53 tent lymphadenopathy resembling multicentric Castleman disease in rhesus macaques (RMs) coinfected wi
54    HIV-associated plasmablastic multicentric Castleman disease is an increasingly frequent diagnosis.
55                         As the complexity of Castleman disease is more fully understood, additional t
56               Finally, although multicentric Castleman disease is not a neoplastic condition, it is a
57 oma (KS) herpesvirus-associated multicentric Castleman disease (KSHV-MCD) is a lymphoproliferative di
58 a herpesvirus (KSHV)-associated multicentric Castleman disease (KSHV-MCD) is characterized by severe
59 imary effusion lymphoma (PEL), and a form of Castleman disease (KSHV-MCD).
60 et of cells in lytically active multicentric Castleman disease lesions.
61                                    Localized Castleman disease manifests as either a solitary, well-c
62                                 Disseminated Castleman disease manifests with diffuse mediastinal lym
63 enesis, both involved in the pathogenesis of Castleman disease, may provide additional unique therape
64 reported as a heralding sign of multicentric Castleman disease (MCD) and other lymphoproliferative di
65 erpesvirus 8 is associated with multicentric Castleman disease (MCD) and primary effusion lymphoma (P
66 ive agent of two B cell tumors, multicentric Castleman disease (MCD) and primary effusion lymphoma (P
67  recognition of KSHV-associated multicentric Castleman disease (MCD) as a distinct lymphoproliferativ
68 a herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a lymphoproliferative disorde
69                                 Multicentric Castleman disease (MCD) is a lymphoproliferative disorde
70 a herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a lymphoproliferative inflamm
71 a herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a polyclonal B-cell lymphopro
72                  HIV-associated multicentric Castleman disease (MCD) is associated with a high risk o
73 ry effusion lymphoma (PEL), and multicentric Castleman disease (MCD) patients.
74 gent of Kaposi sarcoma (KS) and multicentric Castleman disease (MCD), a life-threatening, virally ind
75  effusion lymphoma (PEL) and/or multicentric Castleman disease (MCD), and in 18 (60.0%) of 30 HIV(+),
76 lymphoma (PEL), KSHV-associated multicentric Castleman disease (MCD), and KS inflammatory cytokine sy
77 rimary effusion lymphoma (PEL), multicentric Castleman disease (MCD), and MCD-associated plasmablasti
78 vestigated in patients with KS, multicentric Castleman disease (MCD), and primary effusion lymphoma.
79 itary (EC) PEL, KSHV-associated multicentric Castleman disease (MCD), KSHV+ diffuse large B-cell lymp
80 ary effusion lymphoma (PEL) and multicentric Castleman disease (MCD).
81 lymphoma (PEL), and a subset of multicentric Castleman disease (MCD).
82  lymphoma, and plasma cell-type multicentric Castleman disease (MCD).
83 ry effusion lymphoma (PEL), and multicentric Castleman disease (MCD).
84 ary effusion lymphoma (PEL) and multicentric Castleman disease (MCD).
85 tral/South America), and 2 with multicentric Castleman disease (MCD).
86 ry effusion lymphoma (PEL), and multicentric Castleman disease (MCD).
87 pic (IgMlambda) plasmablasts in multicentric Castleman disease (MCD).
88 been described in some cases of multicentric Castleman disease (MCD).
89 ute to the pathogenesis of KSHV multicentric Castleman disease (MCD).
90                      Patients with localized Castleman disease (n = 24) typically had the hyaline-vas
91                   Patients with disseminated Castleman disease (n = 6) typically had the plasma cell
92 t-line treatment for idiopathic multicentric Castleman disease on the basis of durable efficacy and s
93 rus (HIV)-infected men with KS, multicentric Castleman disease, or primary effusion lymphoma and 8 HI
94 ional criteria were included: a bone lesion, Castleman disease, organomegaly (or lymphadenopathy), en
95 tuximab in posttrans-plantation multicentric Castleman disease patients and non-neoplastic HHV8-assoc
96 nd at least 1 of the other 3 major criteria (Castleman disease, sclerotic bone lesions, or elevated V
97                                              Castleman disease was initially described over 50 years
98 n 30 pathologically proved cases of thoracic Castleman disease were reviewed.
99 on lymphoma and KSHV-associated multicentric Castleman disease, which are B-cell lymphoproliferative
100                            All patients with Castleman disease who were seen at Texas Medical Center,
101 aposi sarcoma, HHV-8-associated multicentric Castleman disease with microlymphomas and a severe hemop

 
Page Top